Left gastric vein embolization during TIPS placement for acute variceal bleeding has no effect on bleeding recurrence: Results of a multicenter study.

Esophageal and gastric varices Gastrointestinal hemorrhage Portal pressure Portosystemic shunt Propensity score Transjugular intrahepatic portosystemic shunt

Journal

Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499

Informations de publication

Date de publication:
May 2023
Historique:
received: 28 10 2022
revised: 06 01 2023
accepted: 10 01 2023
medline: 2 5 2023
pubmed: 6 2 2023
entrez: 5 2 2023
Statut: ppublish

Résumé

The purpose of this study was to evaluate whether concomitant left gastric vein embolization (LGVE) during transjugular intrahepatic portosystemic shunt (TIPS) for acute variceal hemorrhage could reduce the risk of bleeding recurrence. A national multicenter observational study was conducted in 14 centers between January 2019 and December 2020. All cirrhotic patients who underwent TIPS placement for acute variceal bleeding were included. During TIPS procedure, size of left gastric vein (LGV), performance of LGVE, material used for LGVE and portosystemic pressure gradient (PPG) before and after TIPS placement were collected. A propensity score for the occurrence of LGVE was calculated to assess effect of LGVE on rebleeding recurrence at six weeks and one year. A total of 356 patients were included (mean age 57.3 ± 10.8 [standard deviation] years; 283/356 [79%] men). Median follow-up was 11.2 months [interquartile range: 1.2, 13.3]. The main indication for TIPS was pre-emptive TIPS (162/356; 46%), rebleeding despite secondary prophylaxis (105/356; 29%), and salvage TIPS (89/356; 25%). Overall, 128/356 (36%) patients underwent LGVE during TIPS procedure. At six weeks and one year, rebleeding-free survival did not differ significantly between patients who underwent LGVE and those who did not (6/128 [5%] vs. 15/228 [7%] at six weeks, and 11/128 [5%] vs. 22/228 [7%] at one year, P = 0.622 and P = 0.889 respectively). A total of 55 pairs of patients were retained after propensity score matching. In patients without LGVE, the rebleeding rate was not different from those with LGVE (3/55 [5%] vs. 4/55 [7%], P > 0.99, and 5/55 [9%] vs. 6/55[11%], P > 0.99, at six weeks and one year respectively). Multivariable analysis identified PPG after TIPS placement as the only predictor of bleeding recurrence (hazard ratio = 1.09; 95% confidence interval: 1.02-1.18; P = 0.012). In this multicenter national real-life study, we did not observe any benefit of concomitant LGVE during TIPS placement for acute variceal bleeding on bleeding recurrence rate.

Identifiants

pubmed: 36740536
pii: S2211-5684(23)00005-0
doi: 10.1016/j.diii.2023.01.005
pii:
doi:

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-257

Investigateurs

Olivier Chevallier (O)
Thomas Hebert (T)
Antoine Boizet (A)
Ayoub Guerrab (A)
Nicolas Raynaud (N)
Pierre-Quentin Carbillet (PQ)
Victor Dumas (V)
Stéphane Velasco (S)
Bruno Lapuyade (B)
Marie-Annaig Pey (MA)
Emanuele Boatta (E)
Pierre De Marini (P)
Jules Cœur (J)
Pierre Verdot (P)

Informations de copyright

Copyright © 2023 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Paul Calame (P)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France; EA 4662 Nanomedicine Lab, Imagery and Therapeutics, University of Franche-Comté, 25030, Besançon, France.

Mathieu Rostam (M)

Department of Radiology, CHU de Nantes, 44000, Nantes, France.

Louis d'Alteroche (L)

Department of Hepatology, CHU Trousseau, 37550, Tours, France.

Alexandre Malakhia (A)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France; Department of Radiology, CHU Dijon-Bourgogne, 21079, Dijon, France.

Jean-Paul Cervoni (JP)

Department of Hepatology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France.

Delphine Weil (D)

Department of Hepatology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France.

Vincent Di Martino (VD)

Department of Hepatology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France.

Olivier Sutter (O)

Interventional Radiology Unit, Avicenne Hospital, Paris-Seine-Saint-Denis University Hospitals, Assistance-Publique Hopitaux de Paris, 93000, Bobigny, France.

Michel Greget (M)

Department of Radiology, Strasbourg University Hospital, 67200, Strasbourg, France.

Jean-Romain Risson (JR)

Department of Radiology, CHU Brest, 29609, Brest, France.

Mathilde Vionnet (M)

Department of Radiology, CHU de Poitiers, 86000, Poitiers, France.

Antoine Bouvier (A)

Department of Radiology, University Hospital, 49100, Angers, France.

Fatima-Zohra Mokrane (FZ)

Department of Radiology, University of Toulouse III Paul Sabatier, 31062, Toulouse, France.

Julien Ghelfi (J)

Department of Radiology, University of Grenoble-Alpes, 38700, Grenoble, France.

Panteleimon Papadopoulos (P)

Department of Radiology, CHU de Bordeaux, 33400, Bordeaux, France.

Christian Sangel (C)

Department of Radiology, University of Grenoble-Alpes, 38700, Grenoble, France.

Agnes Rodes (A)

Department of Radiology, Hôpital de la Croix Rousse, Centre Hospitalier Universitaire de Lyon, 69004, Lyon, France.

Jean Goupil (J)

Department of Radiology, CHU de Nîmes, 30900, Nîmes, France.

Eric Delabrousse (E)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030, Besançon, France; EA 4662 Nanomedicine Lab, Imagery and Therapeutics, University of Franche-Comté, 25030, Besançon, France.

Frederic Douane (F)

Department of Radiology, CHU de Nantes, 44000, Nantes, France.

Romaric Loffroy (R)

Department of Radiology, CHU Dijon-Bourgogne, 21079, Dijon, France.
Club Francophone pour l'Étude de l'Hypertension Portale (CFEHTP).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH